Top 5 Target	Count

GCGR x GLP-1R	1
PCSK9(Proprotein convertase subtilisin kexin type 9)	1
LILRB2(Leukocyte immunoglobulin-like receptor subfamily B member 2)	1
KRAS G12C(GTPase KRas G12C)	1
F11(Coagulation factor XI)	1

Drugs associated with MSD R&D (China) Co. Ltd.

Gefapixant Citrate

Target

P2X3 receptor

Mechanism

P2X3 receptor antagonists

Active Org.

Merck Sharp & Dohme BV [+1]

Originator Org.

F. Hoffmann-La Roche Ltd.

Active Indication

Unexplained chronic cough [+1]

Inactive Indication

Acute onset cough [+13]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date20 Jan 2022

Belzutifan

Target

HIF-2α

Mechanism

HIF-2α inhibitors

Active Org.

MSD R&D (China) Co. Ltd. [+9]

Originator Org.

Merck Sharp & Dohme Corp.

Active Indication

Advanced Renal Cell Carcinoma [+24]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date13 Aug 2021

Vericiguat

Target

sGC

Mechanism

sGC stimulants

Active Org.

MSD R&D (China) Co. Ltd. [+6]

Originator Org.

Bayer AG

Active Indication

Reduced ejection fraction co-occurrent and due to chronic heart failure [+13]

Inactive Indication

Coronary Artery Disease [+2]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date19 Jan 2021

152

Clinical Trials associated with MSD R&D (China) Co. Ltd.

CTR20242056 / RecruitingPhase 3

一项在中度至重度活动性克罗恩病受试者中评价Tulisokibart的有效性和安全性的III期、随机、双盲、安慰剂对照研究

[Translation] A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Tulisokibart in subjects with moderately to severely active Crohn's disease

研究1：根据第12周和第52周时达到临床缓解以及达到内镜应答的受试者比例，评价MK-7240与安慰剂相比的有效性。评价MK-7240的安全性和耐受性。研究2：根据第12周时达到临床缓解以及达到内镜应答的受试者比例，评价MK-7240与安慰剂相比的有效性。评价MK-7240的安全性和耐受性。

[Translation]

Study 1: To evaluate the effectiveness of MK-7240 compared to placebo based on the proportion of subjects achieving clinical remission and endoscopic response at Week 12 and Week 52. To evaluate the safety and tolerability of MK-7240. Study 2: To evaluate the effectiveness of MK-7240 compared to placebo based on the proportion of subjects achieving clinical remission and endoscopic response at Week 12. To evaluate the safety and tolerability of MK-7240.

Start Date08 Oct 2024

Sponsor / Collaborator

MSD R&D (China) Co. Ltd.

[+2]

CTR20242869 / RecruitingPhase 2

一项评价MK-2870单药治疗或与其他抗肿瘤药物联合治疗消化道肿瘤的安全性和有效性的I/II期研究。

[Translation] A Phase I/II study evaluating the safety and efficacy of MK-2870 as monotherapy or in combination with other anti-cancer drugs in the treatment of gastrointestinal tumors.

评价MK-2870单药治疗或与其他抗肿瘤药物联合治疗消化道肿瘤的安全性和有效性的I/II期研究。

[Translation]

A Phase I/II study to evaluate the safety and efficacy of MK-2870 as monotherapy or in combination with other anti-cancer drugs in the treatment of gastrointestinal tumors.

Start Date30 Sep 2024

Sponsor / Collaborator

MSD R&D (China) Co. Ltd.

CTR20242627 / RecruitingPhase 3

一项在羟基脲缓解不佳或不耐受的原发性血小板增多症受试者中评价Bomedemstat（MK-3543/IMG-7289）与最佳可用治疗（BAT）相比的安全性和有效性的Ⅲ期、随机、开放性、活性药物对照临床研究

[Translation] A Phase III, randomized, open-label, active-controlled clinical study to evaluate the safety and efficacy of Bomedemstat (MK-3543/IMG-7289) compared with best available therapy (BAT) in subjects with essential thrombocythemia who were inadequately responded to or intolerant of hydroxyurea

在羟基脲缓解不佳或不耐受的原发性血小板增多症受试者中评价Bomedemstat（MK-3543/IMG-7289）与最佳可用治疗（BAT）相比的安全性和有效性

[Translation]

To evaluate the safety and efficacy of Bomedemstat (MK-3543/IMG-7289) compared with best available therapy (BAT) in subjects with essential thrombocythemia who are inadequately responded to or intolerant of hydroxyurea

Start Date26 Sep 2024

Sponsor / Collaborator

MSD R&D (China) Co. Ltd.

[+2]

100 Clinical Results associated with MSD R&D (China) Co. Ltd.

0 Patents (Medical) associated with MSD R&D (China) Co. Ltd.

Literatures (Medical) associated with MSD R&D (China) Co. Ltd.

01 Sep 2024·BMJ Open

Barriers and facilitators to implementing imaging-based diagnostic artificial intelligence-assisted decision-making software in hospitals in China: a qualitative study using the updated Consolidated Framework for Implementation Research

Article

Author: Liao, Xiwen ; Zhang, Jun ; Liu, Larry ; Yao, Chen ; Jin, Feifei

ObjectivesTo identify the barriers and facilitators to the successful implementation of imaging-based diagnostic artificial intelligence (AI)-assisted decision-making software in China, using the updated Consolidated Framework for Implementation Research (CFIR) as a theoretical basis to develop strategies that promote effective implementation.DesignThis qualitative study involved semistructured interviews with key stakeholders from both clinical settings and industry. Interview guide development, coding, analysis and reporting of findings were thoroughly informed by the updated CFIR.SettingFour healthcare institutions in Beijing and Shanghai and two vendors of AI-assisted decision-making software for lung nodules detection and diabetic retinopathy screening were selected based on purposive sampling.ParticipantsA total of 23 healthcare practitioners, 6 hospital informatics specialists, 4 hospital administrators and 7 vendors of the selected AI-assisted decision-making software were included in the study.ResultsWithin the 5 CFIR domains, 10 constructs were identified as barriers, 8 as facilitators and 3 as both barriers and facilitators. Major barriers included unsatisfactory clinical performance (Innovation); lack of collaborative network between primary and tertiary hospitals, lack of information security measures and certification (outer setting); suboptimal data quality, misalignment between software functions and goals of healthcare institutions (inner setting); unmet clinical needs (individuals). Key facilitators were strong empirical evidence of effectiveness, improved clinical efficiency (innovation); national guidelines related to AI, deployment of AI software in peer hospitals (outer setting); integration of AI software into existing hospital systems (inner setting) and involvement of clinicians (implementation process).ConclusionsThe study findings contributed to the ongoing exploration of AI integration in healthcare from the perspective of China, emphasising the need for a comprehensive approach considering both innovation-specific factors and the broader organisational and contextual dynamics. As China and other developing countries continue to advance in adopting AI technologies, the derived insights could further inform healthcare practitioners, industry stakeholders and policy-makers, guiding policies and practices that promote the successful implementation of imaging-based diagnostic AI-assisted decision-making software in healthcare for optimal patient care.

06 Mar 2024·Perspectives in Psychiatric Care

Mental and Physical Symptoms and Perceived Health Risks of Pregnant and Postpartum Women following the Significant Shift in COVID-19 Management in China: A Cross-Sectional Survey

Author: Shen, Qing ; Zhou, Zhongliang ; Liu, Shou ; Chen, Chang ; Wang, Yan-Ni ; Lu, Li ; Lai, Sha ; Zhang, TianTian ; Ren, Duo-Mei ; Hu, Ying ; Yan, Yi-Zhu ; Ma, Bing-Cun ; Su, Yu-Qiang

Background. There was a remarkable downgrade in China’s COVID-19 response strategies in January 2023. The COVID-19 infection rate grew rapidly in the early stages following the management policy shift. This study attempted to explore the associations between SARS-CoV-2 infection and mental or physical health status in pregnant and postpartum women and the role of perceived health risks and family members’ SARS-CoV-2 infection status on these associations by capturing the impact of policy shifts in a short period of time. Methods. This cross-sectional study with a random sample from a convenience sample of hospitals was conducted in pregnant and postpartum women in January 2023. Standardized assessment tools were employed to assess anxiety, depressive and physical symptoms, and feelings of hopelessness. Hierarchical multiple logistic regressions were conducted to examine the mechanisms of associations of interests by including a range of sociodemographic factors, self-perceived health, SARS-CoV-2 infection status, and perceived health risks as covariates. Results. Of the 1,013 pregnant and postpartum women aged 32.0 ± 0.3 years, 58.2% (n = 590) were diagnosed with COVID-19, and 49.4% (n = 500) had family members who were infected with SARS-CoV-2. Nearly 98% of the included participants took measures to prevent SARS-CoV-2 infection. A COVID-19 diagnosis was positively associated with feelings of hopelessness (OR = 1.68, 95% CI: 1.20–2.35), probable anxiety (OR = 6.42, 95% CI: 2.18–24.61), possible depression (OR = 2.56, 95% CI: 1.07–6.70), and physical symptoms (OR = 6.28, 95% CI: 1.63–42.03) after adjusting for sociodemographic and health characteristics, while the associations presented no statistical significance when family members’ SARS-CoV-2 infection status and perceived health risks were introduced into the models. Conclusions. Our results suggested that pregnant and postpartum women may experience physical and mental health challenges when they or their family members contracted COVID-19 in the context of a considerable shift in COVID-19 management. Early detection of poor health status and its risk factors for vulnerable groups during shifts in health policy and administrative practice is very necessary, and health services, including easy access to psychosocial support and obstetric counselling, should be prioritized.

26 Jan 2024·Medicine

Comparing verum and sham acupoint catgut embedding for adults with obesity: A systematic review and meta-analysis of randomized clinical trials

Review

Author: Zhao, Wei-wei ; Zhang, Yu-ying ; Zhang, Qin-hong ; Mah, Jeffrey Zhong-xue ; Huang, Jia-qi ; Li, Xiao-ling ; Yue, Jin-huan ; Yang, Guan-hu ; Li, Ang ; Wang, Yu-lin

Background:Previous clinical trials have reported that acupoint catgut embedding (ACE) is a useful modality for weight loss. However, no study has specifically investigated the effectiveness and safety of comparing verum and sham ACE in adults with obesity. Thus, this study aimed to evaluate the effectiveness and safety of comparing verum and sham ACE in obese adults.Methods:A comprehensive literature search was conducted in the electronic databases of PUBMED, EMBASE, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, China Science and Technology Journal Database, and China Biomedical Literature Service System from inception to April 1, 2022. Randomized clinical trials that focused on evaluating the effectiveness of comparing verum and sham ACE in adults with obesity were included. The primary outcomes included reduction in body weight, body mass index, hip circumference, and waist circumference. The secondary outcomes consisted of a decrease in body fat percentage and the occurrence rate of adverse events. The methodological quality of the included randomized clinical trials was evaluated using the Cochrane Risk-of-bias tool. Statistical analysis was performed using RevMan 5.4 software.Results:Six trials involving 679 adults with obesity were included in this study and entered in the data analysis of systematic review and meta-analysis. Results of the meta-analysis revealed significant reduction in body weight (mean difference [MD] = −1.68, 95% confidence intervals (CI) [−2.34, −1.01], I2 = 51%, P < .001), body mass index (MD = −0.51, 95% CI [−0.81, −0.21], I2 = 74%, P < .001), hip circumference (MD = −1.11, 95% CI [−1.67, −0.55], I2 = 0%, P < .001), waist circumference (MD = −2.42, 95% CI [−3.38, −1.45], I2 = 68%, P < .001), and decrease in body fat percentage (MD = −0.83, 95% CI [−1.30, −0.36], I2 = 16%, P < .001) in comparing verum and sham ACE. However, no significant difference was identified in AEs (odds ratio = 1.53, 95% CI [0.80, 2.95], I2 = 0%, P = .20) between the 2 groups.Conclusion:ACE is effective in the treatment of obesity in adults with safety profile. Further studies with higher quality and larger sample size are warranted to confirm the current findings.

100 Deals associated with MSD R&D (China) Co. Ltd.

100 Translational Medicine associated with MSD R&D (China) Co. Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

Phase 1 Clinical

Phase 2 Clinical

Phase 3 Clinical

NDA/BLA

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Pembrolizumab ( PD-1 )	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma More	Approved
Belzutifan ( HIF-2α )	-	NDA/BLA
Human papillomavirus 9-valent vaccine, recombinant (Merck Sharp & Dohme)	HPV-related carcinoma More	NDA/BLA
Tucatinib ( HER2 )	HER2 Positive Colorectal Cancer More	Phase 3
Pembrolizumab/vibostolimab ( PD-1 x TIGIT )	PD-L1 positive Non-Small Cell Lung Cancer More	Phase 3

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis